Phase II Study of Pembrolizumab (MK-3475) in Combination With Standard Therapy for Newly Diagnosed Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2018
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Temozolomide (Primary)
- Indications Astrocytoma; Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 25 Sep 2018 Status changed from recruiting to suspended as per study design. Patients currently on study are being followed according to the protocol.
- 31 Aug 2018 Biomarkers information updated
- 22 Jun 2018 Status changed from suspended to recruiting.